시간 외 거래: 10.65

Oric Pharmaceuticals Inc (ORIC)

Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스

Oric Pharmaceuticals Inc (ORIC)

Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스

ORIC Pharmaceuticals Inc Inc. (ORIC) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle

Trading Day Review: ORIC Pharmaceuticals Inc (ORIC) Loses Momentum, Closing at 10.00 - The Dwinnex

Cantor Fitzgerald Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight Recommendation - MSN

ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume Increase - Defense World

ORIC’s price-to-free cash flow ratio: A closer look at its relevance - US Post News

Brokers Set Expectations for ORIC Pharmaceuticals, Inc.’s FY2024 Earnings (NASDAQ:ORIC) - Defense World

Rhumbline Advisers Has $655,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

ORIC Pharmaceuticals’ (ORIC) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World

Stocks of ORIC Pharmaceuticals Inc (ORIC) are poised to climb above their peers - SETE News

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Victory Capital Management Inc. - Defense World

(ORIC) On The My Stocks Page - Stock Traders Daily

ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 11.6% - Defense World

ORIC Pharmaceuticals (ORIC) – Analysts’ Weekly Ratings Updates - Defense World

Bank of New York Mellon Corp Has $1.32 Million Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

ORIC Pharmaceuticals stock holds Buy rating as analyst sees differentiation from competitor trials - Investing.com Canada

ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Buy Rating from HC Wainwright - Defense World

Quest Partners LLC Boosts Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Openbench, Inc. and Oric Pharmaceuticals, Inc. Launch Success-Driven Discovery Collaboration - Marketscreener.com

The ORIC Pharmaceuticals Inc (ORIC) had a good session last reading, didn’t it? - US Post News

OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration - StockTitan

Analytical Overview: ORIC Pharmaceuticals Inc (ORIC)’s Ratios Tell a Financial Story - The Dwinnex

Cornercap Investment Counsel Inc. Purchases New Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

TD Asset Management Inc Decreases Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock - MSN

ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock - Insider Monkey

ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock - Yahoo Finance

Wharton San Diego Presents: The Future of Biotechnology in San Diego - Procopio

10 Worst Cancer Stocks To Buy Now According to Short Sellers - Insider Monkey

ORIC Pharmaceuticals’ (ORIC) Outperform Rating Reaffirmed at Wedbush - Defense World

Zurcher Kantonalbank Zurich Cantonalbank Purchases 3,188 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

ORIC Pharmaceuticals (NASDAQ:ORIC) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of “Buy” by Brokerages - Defense World

Stifel Nicolaus Initiates Coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) - Defense World

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up to $9.48 - Defense World

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

(ORIC) Technical Data - Stock Traders Daily

Stifel starts ORIC Pharmaceuticals with a buy, $20 target - Investing.com

ORIC Pharmaceuticals, Inc. (ORIC) Stock Price & Chart | Trade Now - Capital.com

A company insider recently sold 40,000 shares of ORIC Pharmaceuticals Inc [ORIC]. Should You Sale? - Knox Daily

Is it possible to buy ORIC Pharmaceuticals Inc(ORIC) shares at a good price now? - US Post News

Nothing is Better Than ORIC Pharmaceuticals Inc (ORIC) stock at the moment - SETE News

ORIC Pharmaceuticals Inc: Weathering Stock Market Storms with 731.50M Market Cap - The InvestChronicle

Taking a Closer Look At ORIC Pharmaceuticals Inc (ORIC) Following Its Recent Trade - Knox Daily

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation - Simply Wall St

Hennion & Walsh Asset Management Inc. Purchases Shares of 102,434 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by California State Teachers Retirement System - Defense World

ORIC’s 2023 Market Dance: Up 1.09% – Time to Invest? - The InvestChronicle

ORIC Pharmaceuticals (FRA:4TZ) EPS (Diluted) : €-1.63 (TTM As of Jun. 2024) - GuruFocus.com

ORIC (ORIC Pharmaceuticals) Cash-to-Debt : 103.40 (As of Jun. 2024) - GuruFocus.com

ORIC (ORIC Pharmaceuticals) Total Inventories : $0.00 Mil (As of Jun. 2024) - GuruFocus.com

ORIC (ORIC Pharmaceuticals) 3-Year EPS without NRI Growth R - GuruFocus.com

ORIC (ORIC Pharmaceuticals) Debt-to-Revenue : N/A (As of Jun. 2024) - GuruFocus.com

ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 3.2% - Defense World

ORIC (ORIC Pharmaceuticals) Intrinsic Value: Projected FCF : $0.00 (As of Aug. 17, 2024) - GuruFocus.com

ORIC Pharmaceuticals (FRA:4TZ) Book Value per Share : €4.15 (As of Jun. 2024) - GuruFocus.com

ORIC Pharmaceuticals (FRA:4TZ) Earnings Yield (Joel Greenbl - GuruFocus.com

ORIC Pharmaceuticals (FRA:4TZ) 14-Day RSI : 56.46 (As of Aug. 17, 2024) - GuruFocus.com

ORIC Pharmaceuticals (FRA:4TZ) EV-to-Revenue : (As of Aug. 17, 2024) - GuruFocus.com

ORIC Pharmaceuticals (FRA:4TZ) 3-Year Book Growth Rate : -19.70% (As of Jun. 2024) - GuruFocus.com

ORIC Pharmaceuticals (FRA:4TZ) 3-Year FCF Growth Rate : 7.00% (As of Jun. 2024) - GuruFocus.com

ORIC Pharmaceuticals (FRA:4TZ) 3-Year EPS without NRI Growt - GuruFocus.com

ORIC Pharmaceuticals (FRA:4TZ) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com

ORIC Pharmaceuticals (FRA:4TZ) Enterprise Value : €339.41 Mil (As of Aug. 19, 2024) - GuruFocus.com

ORIC Pharmaceuticals (FRA:4TZ) Operating Margin % : 0.00% (As of Jun. 2024) - GuruFocus.com

ORIC Pharmaceuticals (FRA:4TZ) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com

ORIC Pharmaceuticals (FRA:4TZ) Cash Ratio : 14.66 (As of Jun. 2024) - GuruFocus.com

ORIC Pharmaceuticals (FRA:4TZ) Long-Term Debt & Capital Lea - GuruFocus.com

ORIC (ORIC Pharmaceuticals) 3-Year Book Growth Rate : -19.70% (As of Jun. 2024) - GuruFocus.com

ORIC과 유사한 종목